Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment ofNaomi Kelman to Board of Directors EffectiveSeptember 14, 2020 , the Board of Directors (the "Board") ofNational Vision Holdings, Inc. ("National Vision" or the "Company") increased the size of the Board by one director (to a total size of eight directors) and filled the vacancy created by such increase by appointingNaomi Kelman , age 61, as a Class I director, effectiveSeptember 14, 2020 .Ms. Kelman will hold office until the date of the Company's 2021 Annual Meeting of Stockholders and until her successor shall be elected and qualified or until her earlier death, resignation, retirement, disqualification or removal.Ms. Kelman served as the President and Chief Executive Officer of Willow, an innovative medtech company inSilicon Valley , from 2014 to 2019. Prior to that,Ms. Kelman served as the Global Division Head of the Novartis Over-the-Counter Division and a member of the Executive Committee from 2011 to 2012. From 2000 to 2011,Ms. Kelman worked at Johnson & Johnson, holding multiple executive and management roles, including as president of Vistakon (Acuvue contact lenses) andLifescan (One Touch diabetes monitor).Ms. Kelman also previously led global expansion initiatives during her time atClairol from 1984 to 2000.Ms. Kelman was selected to our Board because of her leadership and business expertise, her knowledge and background with healthcare companies, including in the optical industry, and her expertise in digital transformation and scaling consumer growth. The Board has determined thatMs. Kelman qualifies as an independent director under the corporate governance standards of NASDAQ and the independence requirements of Rule 10A-3 of the Exchange Act.Ms. Kelman was not appointed to the Board pursuant to any arrangement or understanding with any other person.Ms. Kelman has no family relationships with any director or executive officer of the Company and there are no transactions in whichMs. Kelman has an interest requiring disclosure under Item 404(a) of Regulation S-K. Ms. Kelman will be entitled to the annual compensation paid to independent non-employee directors, consisting of a cash retainer of$75,000 (prorated for 2020), payable quarterly in arrears, and$100,000 paid in restricted stock pursuant to theNational Vision Holdings, Inc. 2017 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). In connection with her appointment to the Board onSeptember 14, 2020 ,Ms. Kelman was granted a$100,000 restricted stock award of the Company's common stock pursuant to the Omnibus Incentive Plan, which will vest in three equal installments on each of the first, second and third anniversaries of the grant date, subject to continued service through the applicable vesting date. The Company andMs. Kelman will enter into the Company's standard form of indemnification agreement for directors, a copy of which was previously filed as Exhibit 10.36 to Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-220719) and is incorporated herein by reference. Resignation ofNate Taylor from Board of Directors OnSeptember 17, 2020 ,Nate Taylor resigned from the Board, effective immediately.Mr. Taylor , who has served on the Board sinceFebruary 2014 , was a Class I director with a term set to expire at the Company's 2021 Annual Meeting of Stockholders. At the time of his resignation,Mr. Taylor served as Chairperson of the Board and a member of the Compensation Committee andNominating and Corporate Governance Committee of the Board.Mr. Taylor confirmed his departure was due to other professional obligations and was not due to any disagreements with the Company. Appointment ofD. Randy Peeler as Chairperson of Board of Directors and to Compensation Committee OnSeptember 17, 2020 , followingMr. Taylor's resignation, the Board decreased the size of the Board by one director (to a total size of seven directors) and appointed Mr.D. Randy Peeler to serve as Chairperson of the Board effective onSeptember 17, 2020 . In addition, effectiveSeptember 17, 2020 , the Board appointedMr. Peeler to the Compensation Committee.
Item 7.01 Regulation FD Disclosure.
A copy of the press release issued by the Company announcing the appointment of
The information included in this Current Report on Form 8-K is being furnished under Item 7.01, "Regulation FD Disclosure" of Form 8-K. As such, the information herein shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
-------------------------------------------------------------------------------- Item 9.01 Financial Statements and Exhibits. (d) Exhibits. See the Exhibit Index immediately preceding the signature page hereto, which is incorporated herein by reference.
--------------------------------------------------------------------------------
© Edgar Online, source